메뉴 건너뛰기




Volumn 23, Issue 1, 2012, Pages 107-111

Bisphosphonate-associated osteonecrosis of the jaws

Author keywords

Bisphosphonates; complications; jaws; osteonecrosis

Indexed keywords

ANTINEOPLASTIC AGENT; BONE DENSITY CONSERVATION AGENT;

EID: 84864668471     PISSN: 09709290     EISSN: 19983603     Source Type: Journal    
DOI: 10.4103/0970-9290.99051     Document Type: Article
Times cited : (6)

References (60)
  • 1
    • 0036727151 scopus 로고    scopus 로고
    • Bisphosphonate mechanism of action
    • Rodan GA, Reszka AA. Bisphosphonate mechanism of action. Curr Mol Med 2002;2:571-7.
    • (2002) Curr Mol Med , vol.2 , pp. 571-7
    • Rodan, G.A.1    Reszka, A.A.2
  • 2
    • 33747888167 scopus 로고    scopus 로고
    • Osteoporosis, bisfosfonatos y calcitonina
    • Mellibovsky L. Osteoporosis, bisfosfonatos y calcitonina. JANO 2001;61:47-54.
    • (2001) JANO , vol.61 , pp. 47-54
    • Mellibovsky, L.1
  • 3
    • 0032468984 scopus 로고    scopus 로고
    • Bisphosphonates: Mechanisms of action
    • Fleish H. Bisphosphonates: Mechanisms of Action. Endocr Rev 1998;19:80-100.
    • (1998) Endocr Rev , vol.19 , pp. 80-100
    • Fleish, H.1
  • 4
    • 0036148405 scopus 로고    scopus 로고
    • The role of bisphosphonates in breast cancer: Development of bisphosphonates
    • Fleish H. The role of bisphosphonates in breast cancer: Development of bisphosphonates. Breast Cancer Res 2002;4:30-4.
    • (2002) Breast Cancer Res , vol.4 , pp. 30-4
    • Fleish, H.1
  • 5
    • 0015939609 scopus 로고
    • The binding of pyrophosphate and two diphosphonates on hydroxyapatite crystals
    • Jung, A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates on hydroxyapatite crystals. Calcif Tissue Res 1973;11:269-80.
    • (1973) Calcif Tissue Res , vol.11 , pp. 269-80
    • Jung, A.1    Bisaz, S.2    Fleisch, H.3
  • 7
    • 0026694920 scopus 로고
    • Retention of etidronate in human, dog, and rat
    • Kasting GB, Francis MD. Retention of etidronate in human, dog, and rat. J Bone Miner Res 1992;7:513-22.
    • (1992) J Bone Miner Res , vol.7 , pp. 513-22
    • Kasting, G.B.1    Francis, M.D.2
  • 9
    • 0026329441 scopus 로고
    • Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone
    • Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 1991;49:407-15.
    • (1991) Calcif Tissue Int , vol.49 , pp. 407-15
    • Flanagan, A.M.1    Chambers, T.J.2
  • 12
    • 0027193759 scopus 로고
    • Bisphosphonates act on rat bone resorption through the mediation of osteoblasts
    • Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993;91:2004-11.
    • (1993) J Clin Invest , vol.91 , pp. 2004-11
    • Sahni, M.1    Guenther, H.L.2    Fleisch, H.3    Collin, P.4    Martin, T.J.5
  • 13
    • 0035460134 scopus 로고    scopus 로고
    • The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis
    • Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 2001;44:2201-10.
    • (2001) Arthritis Rheum , vol.44 , pp. 2201-10
    • Frith, J.C.1    Monkkonen, J.2    Auriola, S.3    Monkkonen, H.4    Rogers, M.J.5
  • 14
    • 0027436434 scopus 로고
    • Vivo Lipophilic 1, 1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents
    • Ciosek CP, Magnin DR, Harrity TW, Logan JV, Dickson JK, Gordon EM, et al. In vivo Lipophilic 1, 1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents. J Biol Chem 1993;268:24832-7.
    • (1993) J Biol Chem , vol.268 , pp. 24832-7
    • Ciosek, C.P.1    Magnin, D.R.2    Harrity, T.W.3    Logan, J.V.4    Dickson, J.K.5    Gordon, E.M.6
  • 15
    • 0034520352 scopus 로고    scopus 로고
    • Vivo effects of bisphosphonates on the osteoclast mevalonate pathway
    • Fisher JE, Rodan GA, Reszka AA. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000;141:4793-6.
    • (2000) Endocrinology , vol.141 , pp. 4793-6
    • Fisher, J.E.1    Rodan, G.A.2    Reszka, A.A.3
  • 16
    • 0031754521 scopus 로고    scopus 로고
    • Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages
    • Luckman SP, Coxon FP, Ebetino FH, Russell RGG, Rogers MG. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998;13:1668-78.
    • (1998) J Bone Miner Res , vol.13 , pp. 1668-78
    • Luckman, S.P.1    Coxon, F.P.2    Ebetino, F.H.3    Russell, R.G.G.4    Rogers, M.G.5
  • 17
    • 0031977199 scopus 로고    scopus 로고
    • Nitrogencontaining bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of gtp-binding proteins, including ras
    • Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MG. Nitrogencontaining bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of gtp-binding proteins, including ras. J Bone Miner Res 1998;13:581-9.
    • (1998) J Bone Miner Res , vol.13 , pp. 581-9
    • Luckman, S.P.1    Hughes, D.E.2    Coxon, F.P.3    Russell, R.G.G.4    Rogers, M.G.5
  • 18
    • 0033554651 scopus 로고    scopus 로고
    • Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates
    • Van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999;264:108-11.
    • (1999) Biochem Biophys Res Commun , vol.264 , pp. 108-11
    • Van Beek, E.1    Pieterman, E.2    Cohen, L.3    Löwik, C.4    Papapoulos, S.5
  • 20
    • 0031036965 scopus 로고    scopus 로고
    • Bisphosphonates: Preclinical aspects and use in osteoporosis
    • Fleish HA. Bisphosphonates: Preclinical aspects and use in osteoporosis. Ann Med 1997;29:55-62.
    • (1997) Ann Med , vol.29 , pp. 55-62
    • Fleish, H.A.1
  • 21
    • 0037112368 scopus 로고    scopus 로고
    • Bisphosphonates inhibit angiogenesis in vitro and testosteronastimulated vascular regrowth in the ventral prostate in castrated rats
    • Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates inhibit angiogenesis in vitro and testosteronastimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-44.
    • (2002) Cancer Res , vol.62 , pp. 6538-44
    • Fournier, P.1    Boissier, S.2    Filleur, S.3    Guglielmi, J.4    Cabon, F.5    Colombel, M.6
  • 22
    • 0036062211 scopus 로고    scopus 로고
    • Pharmacologic profile of zoledronic acid;a highly potent inhibitor of bone resorption
    • Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid;a highly potent inhibitor of bone resorption. Drug Rev Res 2002;55:210-44.
    • (2002) Drug Rev Res , vol.55 , pp. 210-44
    • Green, J.R.1    Rogers, M.J.2
  • 24
    • 0041331740 scopus 로고    scopus 로고
    • Alendronate has a residual effect on bone mass in postmenopausal danish women up to 7 years after treatment withdrawal
    • Bagger YZ, Tanko LB, Alexandersen P, Ravn P, Christiansen C. Alendronate has a residual effect on bone mass in postmenopausal danish women up to 7 years after treatment withdrawal. Bone 2003;33:301-7.
    • (2003) Bone , vol.33 , pp. 301-7
    • Bagger, Y.Z.1    Tanko, L.B.2    Alexandersen, P.3    Ravn, P.4    Christiansen, C.5
  • 25
    • 24044431619 scopus 로고    scopus 로고
    • Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease
    • Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005;353:898-908.
    • (2005) N Engl J Med , vol.353 , pp. 898-908
    • Reid, I.R.1    Miller, P.2    Lyles, K.3    Fraser, W.4    Brown, J.P.5    Saidi, Y.6
  • 28
    • 13844297617 scopus 로고    scopus 로고
    • Ibandronate in metastatic bone disease: A review of preclinical data
    • Bauss F, Body JJ. Ibandronate in metastatic bone disease: A review of preclinical data. Anticancer Drugs 2005;16:107-8.
    • (2005) Anticancer Drugs , vol.16 , pp. 107-8
    • Bauss, F.1    Body, J.J.2
  • 29
    • 0035312469 scopus 로고    scopus 로고
    • Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases
    • Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-200.
    • (2001) Cancer , vol.91 , pp. 1191-200
    • Berenson, J.R.1    Rosen, L.S.2    Howell, A.3    Porter, L.4    Coleman, R.E.5    Morley, W.6
  • 30
    • 4644261592 scopus 로고    scopus 로고
    • Mechanisms of bone metastasis
    • Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.
    • (2004) N Engl J Med , vol.350 , pp. 1655-64
    • Roodman, G.D.1
  • 32
    • 0036895051 scopus 로고    scopus 로고
    • Bilateral acute anterior uveitis after alendronate
    • Malik AR, Campbell SH, Toma NM. Bilateral acute anterior uveitis after alendronate. Br J Ophthalmol 2002;86:1443.
    • (2002) Br J Ophthalmol , vol.86 , pp. 1443
    • Malik, A.R.1    Campbell, S.H.2    Toma, N.M.3
  • 34
    • 0037309091 scopus 로고    scopus 로고
    • Scleritis and other ocular side effects associated with pamidronate disodium
    • Fraunfelder FW, Fraunfelder FT, Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 2003;135:219-22.
    • (2003) Am J Ophthalmol , vol.135 , pp. 219-22
    • Fraunfelder, F.W.1    Fraunfelder, F.T.2    Jensvold, B.3
  • 35
    • 14644439945 scopus 로고    scopus 로고
    • Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy
    • Durnian JM, Olujohungbe A, Kyle G. Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy. Eye 2005;19:221-2.
    • (2005) Eye , vol.19 , pp. 221-2
    • Durnian, J.M.1    Olujohungbe, A.2    Kyle, G.3
  • 36
    • 0015130762 scopus 로고
    • The treatment of osteoporosis with disodium ethane-1-hydroxy-1, 1-diphosphonate
    • Jowsey J, Riggs BL, Kelly PJ, Hoffman DL, Bordier P. The treatment of osteoporosis with disodium ethane-1-hydroxy-1, 1-diphosphonate. J Lab Clin Med 1971;78:574-84.
    • (1971) J Lab Clin Med , vol.78 , pp. 574-84
    • Jowsey, J.1    Riggs, B.L.2    Kelly, P.J.3    Hoffman, D.L.4    Bordier, P.5
  • 40
    • 0030093323 scopus 로고    scopus 로고
    • Symptomatic hypocalcaemia after intravenous pamidronate
    • McIntyre E, Bruera E. Symptomatic hypocalcaemia after intravenous pamidronate. J Palliat Care 1996;12:46-7.
    • (1996) J Palliat Care , vol.12 , pp. 46-7
    • McIntyre, E.1    Bruera, E.2
  • 41
    • 0035002570 scopus 로고    scopus 로고
    • Prolonged symptomatic hypocalcaemia with pamidronate administration and subclinical hypoparathyroidism
    • Mishra A, Wong L, Jonklaas J. Prolonged symptomatic hypocalcaemia with pamidronate administration and subclinical hypoparathyroidism. Endocrine 2001;14:159-64.
    • (2001) Endocrine , vol.14 , pp. 159-64
    • Mishra, A.1    Wong, L.2    Jonklaas, J.3
  • 42
    • 0025965735 scopus 로고
    • Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcemia of malignancy
    • Fraser WD, Logue FC, Gallacher SJ, O'Reilly DS, Beastall GH, Ralston SH, et al. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcemia of malignancy. Bone Miner 1991;12:113-21.
    • (1991) Bone Miner , vol.12 , pp. 113-21
    • Fraser, W.D.1    Logue, F.C.2    Gallacher, S.J.3    O'Reilly, D.S.4    Beastall, G.H.5    Ralston, S.H.6
  • 45
    • 0030756221 scopus 로고    scopus 로고
    • Hypercalcemia of malignancy
    • Mundy GR, Guise TA. Hypercalcemia of malignancy. Am J Med 1997;103:134-45.
    • (1997) Am J Med , vol.103 , pp. 134-45
    • Mundy, G.R.1    Guise, T.A.2
  • 46
    • 29844444565 scopus 로고    scopus 로고
    • Alendronate and mouth ulcers: Careful interrogation of the patient to start with
    • Schmutz JL, Barbaud A, Trechot P. Alendronate and mouth ulcers: Careful interrogation of the patient to start with. Ann Dermatol Venereol 2005;132:930.
    • (2005) Ann Dermatol Venereol , vol.132 , pp. 930
    • Schmutz, J.L.1    Barbaud, A.2    Trechot, P.3
  • 47
    • 0042861578 scopus 로고    scopus 로고
    • Pamidronate (Aredia) and zolendronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic
    • Marx RE. Pamidronate (Aredia) and zolendronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7.
    • (2003) J Oral Maxillofac Surg , vol.61 , pp. 1115-7
    • Marx, R.E.1
  • 48
    • 32644489792 scopus 로고    scopus 로고
    • Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: An update
    • Jiménez Y, Bagán JV. Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: An update. Med Oral Patol Oral Cir Bucal 2005;10:88-91.
    • (2005) Med Oral Patol Oral Cir Bucal , vol.10 , pp. 88-91
    • Jiménez, Y.1    Bagán, J.V.2
  • 51
    • 27344453813 scopus 로고    scopus 로고
    • Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment
    • Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75.
    • (2005) J Oral Maxillofac Surg , vol.63 , pp. 1567-75
    • Marx, R.E.1    Sawatari, Y.2    Fortin, M.3    Broumand, V.4
  • 52
    • 17644406724 scopus 로고    scopus 로고
    • Bisphosphonates and avascular necrosis of the jaw: A possible association
    • Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: A possible association. Med J Aust 2005;182:413-5.
    • (2005) Med J Aust , vol.182 , pp. 413-5
    • Carter, G.1    Goss, A.N.2    Doecke, C.3
  • 53
    • 0642316721 scopus 로고    scopus 로고
    • Bisphosphanates and oral cavity avascular bone necrosis
    • Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:4253-4.
    • (2003) J Clin Oncol , vol.21 , pp. 4253-4
    • Migliorati, C.A.1
  • 55
    • 0003320840 scopus 로고    scopus 로고
    • PS-341(Bortazomib) is active in multiple myeloma Preliminary report of a phase I trial of the proteasome inhibitor PS- 341 in patients with hematologic malignancies
    • Stinchcombe TE, Mitchell BS, Depcets-Smith N, Orlowski RZ, Shea TC, Baldwin AS et al. PS-341(Bortazomib) is active in multiple myeloma. Preliminary report of a phase I trial of the proteasome inhibitor PS- 341 in patients with hematologic malignancies. Blood 2000;96:516.
    • (2000) Blood , vol.96 , pp. 516
    • Stinchcombe, T.E.1    Mitchell, B.S.2    Depcets-Smith, N.3    Orlowski, R.Z.4    Shea, T.C.5    Baldwin, A.S.6
  • 58
    • 27644590803 scopus 로고    scopus 로고
    • Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: A report of three cases
    • Katz H. Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: A report of three cases. J Endod 2005;31:831-4.
    • (2005) J Endod , vol.31 , pp. 831-4
    • Katz, H.1
  • 59
    • 12844260206 scopus 로고    scopus 로고
    • Recommendations for zoledronic acid treatment of patients with bone metastases
    • Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 2005;10:52-62.
    • (2005) Oncologist , vol.10 , pp. 52-62
    • Berenson, J.R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.